Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Beat AML® Marks 10 Years of Advancing Precision Medicine for Acute Myeloid Leukemia

      Blood Cancer United

      News provided by

      Blood Cancer United® formerly The Leukemia & Lymphoma Society

      Nov 17, 2026, 10:15 ET

      Share this article

      Share this article


      Blood Cancer United-led master clinical trial has provided genomic analysis to more than 2,000 patients and advanced treatment approaches from early studies into phase 3 research

      WASHINGTON, Nov. 17, 2026 /PRNewswire/ -- Blood Cancer United® today marked the 10th anniversary of its Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer.

      Blood Cancer United launched Beat AML in 2016 to challenge the one-size-fits-all approach that had long defined acute myeloid leukemia, or AML, treatment. The trial uses advanced genomic technology to identify the genetic changes driving each patient's AML and match eligible patients to treatment sub-studies based on the biology of their disease.

      Continue Reading
      Blood Cancer United's Beat AML Master Clinical Trial has revolutionized acute myeloid leukemia treatment over the past decade. Patients are living longer, with less side effects from their treatments and a better quality of life
      Blood Cancer United's Beat AML Master Clinical Trial has revolutionized acute myeloid leukemia treatment over the past decade. Patients are living longer, with less side effects from their treatments and a better quality of life

      Since its launch, more than 2,000 patients have participated in the Beat AML master protocol, receiving genomic analysis to help inform their treatment options. In addition, more than 720 patients have enrolled across 17 clinical sub-studies, evaluating investigational treatments in collaboration with pharmaceutical and biotechnology companies. Beat AML findings have contributed to 65 publications and abstracts.

      "Beat AML began with a bold scientific question: Could we rapidly understand the biology of each patient's AML and use that information to guide precision treatment?" said E. Anders Kolb, M.D., president and CEO of Blood Cancer United. "Today, we know that advanced diagnostics not only guide treatment but also improve outcomes. With that foundation, Beat AML united patients, researchers, clinicians, and industry partners around a shared goal. Together, we have built a master clinical trial that has evolved with the state-of-the-art, accelerated the study of promising treatments, and helped create more time and better outcomes for people with AML." 

      Meeting the urgent need for better AML treatments

      An estimated 22,700 people in the United States will be diagnosed with AML in 2026. It is one of the most aggressive blood cancers and is difficult to treat because it includes biologically distinct subtypes and rare genetic mutations that may respond differently to treatment.

      Approximately 1 in 3 people living with AML survive five years after diagnosis, and incidence begins to increase notably among people age 55 and older. Many older patients cannot tolerate intensive chemotherapy, while patients whose disease returns or stops responding to treatment have limited options.

      Blood Cancer United initially designed Beat AML for adults age 60 and older with newly diagnosed AML. With genomic analysis provided by Foundation Medicine, the trial set out to complete comprehensive genomic and cytogenomic analysis and assign treatment within seven days. Findings published in Nature Medicine in 2020 showed that Beat AML achieved that primary endpoint for 94.7% of eligible patients. Further, patients who enrolled in Beat AML sub-studies also had longer overall survival than those who received standard treatment.

      Beat AML demonstrated that it's feasible to quickly gather comprehensive genomic information to determine targeted treatment options for AML. This remains foundational today since genomic testing plays an increasingly important role in treating this fast-moving, aggressive cancer.

      Beat AML's impact over the past decade

      Beat AML brings together academic investigators, treatment centers, genomic experts, pharmaceutical and biotechnology companies, data specialists, and clinical research organizations through shared infrastructure that can adapt as the science evolves.

      Blood Cancer United Celebrates 10 Years of Beat AML

      Over the past decade, Beat AML has expanded its scientific impact for people with AML by:

      • Establishing a master-trial that could be modeled: Beat AML demonstrated how a nonprofit-led master clinical trial could integrate genomic screening, multiple treatment sub-studies and a broad network of research collaborators. In 2021, Beat AML researchers and operational partners published lessons in a peer-reviewed journal that provided insights for other organizations to model when developing master trials. In 2022, Blood Cancer United launched PedAL, extending the precision medicine master-trial approach to pediatric acute leukemia.
      • Expanding the breadth of clinical research: Beat AML now spans phase 1b, phase 2 and phase 3 research, allowing multiple sub-studies to evaluate targeted therapies and treatment combinations for different forms of AML. Originally focused on adults age 60 and older with newly diagnosed AML, Beat AML now includes patients age 18 and older, patients with myelodysplastic syndrome (MDS), and relapsed/refractory AML or MDS.
      • Answering questions arising in patient care: Recent results published in Blood for the OPTI-AML sub-study provided new information about whether some older patients with newly diagnosed AML could receive a shorter schedule of venetoclax when it is given with azacitidine. The study was important since venetoclax schedules are often shortened in clinical practice because of side effects. The study found that the optimal duration of venetoclax varies by AML genetic mutation, reinforcing the need to tailor treatment based on disease biology. 
      • Moving promising approaches into registration-directed clinical studies: Evidence generated through Beat AML has supported the progression of an investigational menin inhibitor combination from phase 1b research into phase 3 evaluation (see below details for BAML-16-001-S17 and BAML-16-001-S26).

      Leading the next phase of AML treatment

      Beat AML's active portfolio spans the clinical development continuum, from early-stage studies of new treatment combinations to phase 3 trials. Internationally, Beat AML and its investigators are participating in global phase 3 studies sponsored by HOVON, a non-profit foundation located in The Netherlands.

      Following are the current active substudies of Beat AML:

      Study or program

      Details

      BAML-16-001-S17 Phase 1b dose escalation and expansion

      (Enrollment complete)

      Revumenib with azacitidine and venetoclax in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who were not eligible for intensive chemotherapy.

      Findings supported continued evaluation of the combination in phase 3 research. Read the phase 1b results in the Journal of Clinical Oncology.

      BAML-16-001-S24 Phase 1b safety run-in/Phase 2

      (Actively recruiting)

      Ficlatuzumab with azacitidine and venetoclax in adults with newly diagnosed AML across molecular subtypes.

      BAML-16-001-S25/HO181 

      Phase 3

      (Actively recruiting)

      Bleximenib with standard induction and consolidation chemotherapy, in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who are eligible for intensive chemotherapy.

      BAML-16-001-S26/HO177 

      Phase 3

      (Actively recruiting)

      Revumenib with azacitidine and venetoclax in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who are not eligible for intensive chemotherapy.

      "It has taken nearly a decade to build the science and infrastructure needed to support potentially practice-changing studies," said Alice Mims, M.D., Beat AML chief medical officer and a hematologist at The Ohio State University Comprehensive Cancer Center. "As Beat AML enters its second decade, we have an opportunity to build on that foundation by answering important treatment questions, evaluating new approaches and bringing clinical trials closer to patients. Our goal is to generate evidence that helps people with AML and their physicians make more informed treatment decisions and, ultimately, live longer, fuller lives." 

      Beat AML research at ASH 2026

      Beat AML investigators will present three oral abstracts and three posters at the 2026 American Society of Hematology Annual Meeting and Exposition from Dec. 12-15, 2026, in New Orleans.

      A key oral presentation will include updated results from a Phase 1b trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed patients with NPM1-mutated or KMT2A-rearranged AML. These findings support the ongoing randomized phase 3 study, BAML-16-001-S26/HO177, which is mentioned above. (Oral presentation; Abstract 662).

      Four presentations will feature findings from OPTI-AML, the Beat AML sub-study comparing 14-day and 28-day courses of venetoclax in combination with azacitidine in older adults with newly diagnosed acute myeloid leukemia. Findings include:

      • Genotype-specific molecular dynamics and molecular tumor load can help guide treatment intensity selection. (Oral presentation; Abstract 389)
      • Existing timing guidance for hematologic recovery (return to normal blood counts) may underrecognize meaningful long-term responses. (Oral presentation; Abstract 897)
      • A baseline for future studies of wearable devices to help address whether remote monitoring is beneficial in an age of decentralized trials. (Poster presentation; Abstract 4600)
      • Prognostic Risk Integration for Survival Modeling (PRISM), a recently developed risk model, has potential use for risk stratification in clinical trials to identify patients who may benefit from new treatment approaches. (Poster presentation; Abstract 3476)

      A sixth presentation is a retrospective analysis of data in a cohort of Beat AML patients with myeloproliferative neoplasms (MPN), which underscores the need for continued development of novel approaches and trials inclusive of this high-risk population. (Poster presentation; Abstract 3794)

      Blood Cancer United proudly and gratefully acknowledges the Kellenyi family for their generous donation in memory of John Kellenyi, and the Harry T. Mangurian, Jr. Foundation for its philanthropy in honor of Harry T. Mangurian, Jr. 

      About Blood Cancer United®

      Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research and advocacy. The organization's mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of patients and their families, volunteers, health care providers, scientists, staff, partners, fundraisers and philanthropists who believe all people with blood cancer deserve longer, fuller lives. For support and to learn more, visit Blood Cancer United.

      About Beat AML®

      The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match eligible patients with promising targeted treatments based on the unique genetic mutations driving their disease.

      Beat AML evaluates multiple therapies simultaneously through multiple clinical sub-studies. The trial has generated results showing improved survival and quality of life among patients who received treatment matched to the molecular characteristics of their cancer. Over the past decade, Beat AML has grown into a powerful research ecosystem that brings together pharmaceutical and biotechnology companies, genomic testing experts, data specialists, regulatory agencies, treatment centers and other collaborators working to develop better, safer treatments for people with acute myeloid leukemia.

      For more information, visit Beat AML.

      Media contact:
      Sandra Salviejo
      Senior Director, communications
      [email protected]

      SOURCE Blood Cancer United® formerly The Leukemia & Lymphoma Society

      Modal title

      Also from this source

      Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer

      Blood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer

      Blood Cancer United® today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation for...

      Blood Cancer Survival Has Improved Substantially, but Outcomes Vary Widely by Disease; Males Account for Nearly 56% of Diagnoses

      Blood Cancer Survival Has Improved Substantially, but Outcomes Vary Widely by Disease; Males Account for Nearly 56% of Diagnoses

      Blood Cancer United released Facts 2025-2026: Updated Data on Blood Cancers, a comprehensive look at who is affected by blood cancer and how...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.